Long-term Follow-up of Patients with Relapsed or Refractory Non-Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study.
Matthew S DavidsAndrew W RobertsVaishalee P KenkreWilliam G WierdaAbhijeet KumarThomas J KippsMichelle BoyerAhmed Hamed SalemJohn C PeskoJennifer A ArztMargaret MantasSu Y KimJohn Francis SeymourPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Venetoclax monotherapy has a manageable safety profile and achieves durable responses in a subset of patients with FL, MCL, WM, and MZL, particularly in those who achieve CR. Further research is warranted on combination strategies to enhance the durability of response to venetoclax.